Suzuki F, et al. - In patients with chronic hepatitis B (CHB) infection, researchers discovered the antiviral potency and viral breakthrough rate after 10 years of continuous entecavir treatment. Findings suggested an association of long-term entecavir treatment of nucleos(t)ide analogue-naïve CHB patients with an excellent viral response and a low rate of entecavir-resistant mutations at 10 years. They found that predictors of hepatitis B surface antigen (HBsAg) seroclearance during entecavir treatment were baseline HBsAg levels and genotype. No serious adverse events during treatment were reported in this analysis.